SPOK Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of 9.46% compared to Spok Holdings, Inc.'s net margin of -41.48%. Spok Holdings, Inc.'s return on equity of 10.88% beat DarioHealth Corp.'s return on equity of -41.55%.

Spok Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 61.17%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 51.45%. Given that Spok Holdings, Inc. has higher upside potential than DarioHealth Corp., analysts believe Spok Holdings, Inc. is more attractive than DarioHealth Corp..

Spok Holdings, Inc. has a beta of 0.438, which suggesting that the stock is 56.19% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.

Spok Holdings, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 9.59%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spok Holdings, Inc. pays 171.77% of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.

Spok Holdings, Inc. quarterly revenues are $33.9M, which are larger than DarioHealth Corp. quarterly revenues of $5M. Spok Holdings, Inc.'s net income of $3.2M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, Spok Holdings, Inc.'s price-to-earnings ratio is 16.28x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spok Holdings, Inc. is 1.94x versus 6.69x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GoodRx Holdings, Inc. has a net margin of 9.46% compared to Spok Holdings, Inc.'s net margin of 0.57%. Spok Holdings, Inc.'s return on equity of 10.88% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

Spok Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 61.17%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 85.07%. Given that GoodRx Holdings, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Spok Holdings, Inc..

Spok Holdings, Inc. has a beta of 0.438, which suggesting that the stock is 56.19% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

Spok Holdings, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 9.59%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spok Holdings, Inc. pays 171.77% of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

Spok Holdings, Inc. quarterly revenues are $33.9M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Spok Holdings, Inc.'s net income of $3.2M is higher than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Spok Holdings, Inc.'s price-to-earnings ratio is 16.28x while GoodRx Holdings, Inc.'s PE ratio is 32.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spok Holdings, Inc. is 1.94x versus 1.26x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of 9.46% compared to Spok Holdings, Inc.'s net margin of 11.54%. Spok Holdings, Inc.'s return on equity of 10.88% beat National Research Corp.'s return on equity of 61.55%.

Spok Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 61.17%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Spok Holdings, Inc. has higher upside potential than National Research Corp., analysts believe Spok Holdings, Inc. is more attractive than National Research Corp..

Spok Holdings, Inc. has a beta of 0.438, which suggesting that the stock is 56.19% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Spok Holdings, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 9.59%. National Research Corp. offers a yield of 2.94% to investors and pays a quarterly dividend of $0.12 per share. Spok Holdings, Inc. pays 171.77% of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Spok Holdings, Inc.'s is not.

Spok Holdings, Inc. quarterly revenues are $33.9M, which are smaller than National Research Corp. quarterly revenues of $34.6M. Spok Holdings, Inc.'s net income of $3.2M is lower than National Research Corp.'s net income of $4M. Notably, Spok Holdings, Inc.'s price-to-earnings ratio is 16.28x while National Research Corp.'s PE ratio is 23.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spok Holdings, Inc. is 1.94x versus 2.67x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of 9.46% compared to Spok Holdings, Inc.'s net margin of -2156852.78%. Spok Holdings, Inc.'s return on equity of 10.88% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

Spok Holdings, Inc. has a consensus price target of $20.00, signalling upside risk potential of 61.17%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 721.92%. Given that Predictive Oncology, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe Predictive Oncology, Inc. is more attractive than Spok Holdings, Inc..

Spok Holdings, Inc. has a beta of 0.438, which suggesting that the stock is 56.19% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

Spok Holdings, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 9.59%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spok Holdings, Inc. pays 171.77% of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

Spok Holdings, Inc. quarterly revenues are $33.9M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. Spok Holdings, Inc.'s net income of $3.2M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, Spok Holdings, Inc.'s price-to-earnings ratio is 16.28x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spok Holdings, Inc. is 1.94x versus 16.78x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.